XML 55 R23.htm IDEA: XBRL DOCUMENT
v3.19.1

Other Consolidated Financial Statement Detail | 3 Months Ended
--- | ---
Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Other Consolidated Financial Statement Detail | Other Consolidated Financial Statement Detail Other Income (Expense), Net Components of other income (expense), net, are summarized as follows:
| For the Three Months Ended March 31,
(In millions) | 2019 |  | 2018
Interest income | $ | 31.2 |  |  | $ | 26.7 |
Interest expense | (47.9 | ) |  | (50.5 | )
Gain (loss) on investments, net | 376.4 |  |  | (14.4 | )
Foreign exchange gains (losses), net | (2.2 | ) |  | (1.0 | )
Other, net | (0.2 | ) |  | (1.8 | )
Total other income (expense), net | $ | 357.3 |  |  | $ | (41.0 | )
For the three months ended March 31, 2019, gain (loss) on investments, net, as reflected in the table above, substantially relate to marketable equity securities held at March 31, 2019. The increase in gain (loss) on investments, net, compared to the prior year period, was primarily due to an increase in the fair value in our investment in Ionis' common stock as well as an increase in the value of a non-marketable equity security. For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, Collaborative and Other Relationships, to these condensed consolidated financial statements. For additional information on our investment in Ionis, please read Note 19, Collaborative and Other Relationships, to our consolidated financial statements included in our 2018 Form 10-K. Accrued Expenses and Other Accrued expenses and other consists of the following:
(In millions) | As of March 31, 2019 |  | As of December 31, 2018
Revenue-related reserves for discounts and allowances | $ | 907.6 |  |  | $ | 874.7 |
Collaboration expenses | 216.6 |  |  | 261.6 |
Royalties and licensing fees | 195.0 |  |  | 224.7 |
Employee compensation and benefits | 160.8 |  |  | 320.9 |
Current portion of contingent consideration obligations | 147.3 |  |  | 444.8 |
Construction in progress | 99.7 |  |  | 125.2 |
Other | 708.0 |  |  | 609.3 |
Total accrued expenses and other | $ | 2,435.0 |  |  | $ | 2,861.2 |
Other Long-term Liabilities Other long-term liabilities were $1,353.8 million and $1,389.4 million as of March 31, 2019 and December 31, 2018, respectively, and included accrued income taxes totaling $796.1 million and $791.4 million, respectively.

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration